Jing Jin

Jing Jin

Auto-generated profile, based on publicly available information

Jing Jin

Harmony Technology Co., Ltd., Beijing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
GYGuihua Yang
Guihua Yang
JSJiashen Shao
Jiashen Shao
JLJiachen Lin
Jiachen Lin
HYHaixia Yang
Haixia Yang
JJJing Jin
Jing Jin
ZWZhihong Wu
Zhihong Wu
The aim of this study was to investigate the therapeutic efficacy and safety of transplanting human umbilical cord blood‐derived mesenchymal stem cells (hUCB‐MSCs) in the treatment of cartilage injury. First, the articular cartilage defect model in rabbits was constructed. Then, the identified hUCB‐MSCs and rabbit bone marrow stem cells (rBM‐MSCs) were transplanted into the bone defect, respectively, and the cartilage repair effect was observed by hematoxylin‐eosin (HE) staining and immunohistochemistry. Besides, the glycosaminoglycan (GAG) content and biomechanics of the restoration area were also evaluated. In our study, hUCB‐MSCs and rBM‐MSCs exhibited typical MSC characteristics, with positive expressions of CD73, CD105, and CD90 and negative for CD45, CD34, CD14, and HLA‐DR. After the transplantation of hUCB‐MSCs and rBM‐MSCs, the overall quality of cartilage tissue was significantly improved, and the recipients did not show significant side effects in general. However, the expression of matrix metalloproteinase‐13 (MMP‐13) in the de novo tissues of the hUCB‐MSCs and rBM‐MSCs groups was both increased, indicating that the novel tissues may have some potential osteoarthritic changes. In conclusion, our results suggest the therapeutic effect of hUCB‐MSCs transplantation in cartilage regeneration, providing a promising future in the clinical treatment of cartilage injury.